Skip to content
Dosage GuideResearch Reference

Neurotensin Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Neurotensin. All information is for educational purposes only.

Quick Answer

Neurotensin dosage for research purposes varies depending on the target application and animal model. Human trials are limited, making extrapolation challenging. Typical subcutaneous doses in preclinical models range from 0.1-1 mg/kg. Intranasal administration shows promise for CNS effects. No standardized human dosage exists.

→ Neurotensin Benefits→ Neurotensin Side Effects→ Full Neurotensin Profile
Table of Contents

Standard Dosage Range

Research dosing range: No standardized human dosage. Preclinical: 0.1-1 mg/kg

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Antipsychotic Effects (Research)

0.1-0.5 mg/kg1-2x daily
Duration

2-8 weeks

Animal studies. Subcutaneous or intraperitoneal. Targets NTS1 receptors. Consider potential hypothermia.

Analgesia (Research)

0.05-0.2 mg/kg1-2x daily
Duration

1-4 weeks

Animal studies. Intrathecal or subcutaneous. Targets NTS2 receptors. Limited human data.

Metabolic Regulation (Research)

0.2-1 mg/kg1x daily
Duration

4-12 weeks

Animal studies. Subcutaneous. Investigating effects on fat metabolism. Monitor for potential GI side effects.

Neuroprotection (Research)

0.1-0.3 mg/kg1x daily
Duration

2-6 weeks

Animal studies. Investigating hypothermic neuroprotection. Consider route of administration to target CNS.

Timing & Frequency

Timing depends on the target application. For CNS effects, intranasal administration may provide faster onset. Subcutaneous injections can be timed based on half-life and desired effect duration.

Cycle Guidance

Due to limited human data, cycle guidance is largely based on preclinical studies. Shorter cycles (2-8 weeks) with breaks are commonly used. Monitor for any adverse effects and adjust accordingly.

Reconstitution Reference

Quick reference for reconstituting Neurotensin. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeVaries
BAC Water VolumeRefer to manufacturer instructions for desired concentration
Concentration & DrawVaries depending on experimental design and target dosage
StorageRefrigerate after reconstitution. Follow manufacturer instructions.
StabilityConsult manufacturer specifications for reconstituted solution stability.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical dosage of neurotensin for antipsychotic research?
In animal models, neurotensin dosages for antipsychotic research typically range from 0.1-0.5 mg/kg administered subcutaneously or intraperitoneally. Human data is lacking, making dosage extrapolation unreliable.
How is neurotensin typically administered?
In research settings, neurotensin is administered via subcutaneous, intraperitoneal, intrathecal, or intranasal routes. The specific route depends on the target application and desired effect.
What are the potential side effects of neurotensin administration?
Potential side effects observed in preclinical studies include hypothermia, hypotension, changes in GI motility, and alterations in hormone levels. Human data is limited, and the safety profile is not well-established.

Last updated: 2026-02-19